Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01701830
Recruitment Status : Unknown
Verified October 2012 by Kocaeli Derince Education and Research Hospital.
Recruitment status was:  Recruiting
First Posted : October 5, 2012
Last Update Posted : October 5, 2012
Sponsor:
Information provided by (Responsible Party):
Kocaeli Derince Education and Research Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.

Condition or disease
Non-diabetic Chronic Kidney Disease Atherosclerosis

Detailed Description:
Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 85 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease
Study Start Date : October 2012
Estimated Study Completion Date : May 2013

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Case Group
Patients with chronic kidney disease of stage 3-4.
Control group
30 healthy subject


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Department of Nephrology, Check-up clinic
Criteria

Inclusion Criteria:

  • between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion Criteria:

  • Chronic kidney disease of stage 5
  • The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
  • Severe heart failure
  • Stage 2 hypertension
  • Diabetes mellitus
  • Corticosteroid therapy
  • Severe hepatic disease
  • Smoking
  • Inflammatory disease
  • Acute infectious disease
  • Malignancy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01701830


Locations
Layout table for location information
Turkey
Department of Nephrology, Check-up Clinic,Kocaeli Derince Education and Traning Hospital Recruiting
Izmit, Kocaeli, Turkey, 41100
Contact: Rabia TERZI, MD    90262 317 80 00 ext 8110    drrabia1@yahoo.com   
Principal Investigator: Erkan SENGUL, MD         
Sub-Investigator: Gokhan DUYGULU, MD         
Sub-Investigator: Sevim DINDAR, MD         
Sub-Investigator: Fatih BUNUL, MD         
Sponsors and Collaborators
Kocaeli Derince Education and Research Hospital
Investigators
Layout table for investigator information
Principal Investigator: Erkan SENGUL, MD Kocaeli Derince Education and Training Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Kocaeli Derince Education and Research Hospital
ClinicalTrials.gov Identifier: NCT01701830    
Other Study ID Numbers: 2012/02
First Posted: October 5, 2012    Key Record Dates
Last Update Posted: October 5, 2012
Last Verified: October 2012
Keywords provided by Kocaeli Derince Education and Research Hospital:
omentin-1
carotid atherosclerosis
kidney disease
Additional relevant MeSH terms:
Layout table for MeSH terms
Carotid Artery Diseases
Kidney Diseases
Renal Insufficiency, Chronic
Atherosclerosis
Urologic Diseases
Renal Insufficiency
Arteriosclerosis
 Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases